Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01775774 · ClinicalTrials.gov registry record · Phase 1
Human Mesenchymal Stem Cells For Acute Respiratory Distress Syndrome
A Phase 1 study of Acute Respiratory Distress Syndrome, sponsored by Michael A. Matthay.
- Completed
- Registry status
- Phase 1
- Development phase
- 9
- Enrollment target
- 4
- Study locations
NCT01775774 is a Phase 1 study of Acute Respiratory Distress Syndrome that has completed, run by Michael A. Matthay. The registered enrollment target is 9 participants, below the 367-participant average among 31 other Acute Respiratory Distress Syndrome trials with a reported enrollment target (98% lower). The trial reports 4 study locations across 3 states.
The verdict
NCT01775774, a Phase 1 study of Acute Respiratory Distress Syndrome, has completed, sponsored by Michael A. Matthay.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 9 participants
- Enrollment target
- 4
- Study locations
Study Summary
This is a Phase 1, open label, dose escalation, multi-center clinical trial of Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells (hMSCs) for the treatment of Acute Respiratory Distress Syndrome (ARDS). The purpose of this study is to assess the safety of hMSCs in patients with ARDS.
Conditions Studied
Interventions
- BIOLOGICAL Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells
Study Locations (4)
California
- University of California San Francisco Medical Center - San Francisco
- Stanford University Medical Center - Stanford
Massachusetts
- Massachusetts General Hospital - Boston
Pennsylvania
- University of Pittsburgh Medical Center - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2013-07 |
| Est. Completion | 2015-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01775774
The ClinicalTrials.gov registry entry for NCT01775774 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 367-participant average among 31 other Acute Respiratory Distress Syndrome trials with a reported enrollment target (98% lower). The listed sponsor is Michael A. Matthay, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Acute Respiratory Distress Syndrome appearing as the primary indexed condition, and to 1 intervention - of which Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells is the first listed.
NCT01775774 reports 4 study locations spanning 3 distinct geographic areas - top geographies include California, Massachusetts, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT01775774 about?
NCT01775774 is a clinical study titled "Human Mesenchymal Stem Cells For Acute Respiratory Distress Syndrome". This is a Phase 1, open label, dose escalation, multi-center clinical trial of Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells (hMSCs) for the treatment of Acute Respiratory Distress Syndrome (ARDS). The purpose of this study is to assess the safety of hMSCs in patients with ARDS.
What is the current status of trial NCT01775774?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2013-07. Estimated completion is 2015-02.
What conditions does trial NCT01775774 study?
This clinical trial studies the following conditions: Acute Respiratory Distress Syndrome.
What interventions are being tested in trial NCT01775774?
The interventions under investigation include: Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells (BIOLOGICAL).
Who is sponsoring clinical trial NCT01775774?
This trial is sponsored by Michael A. Matthay, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01775774 being conducted?
This trial has 4 study locations across California, Massachusetts, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acute Respiratory Distress Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Safety Study of Inhaled Carbon Monoxide to Treat Pneumonia and Sepsis-Induced Acute Respiratory Distress Syndrome (ARDS)
ACTIVE NOT RECRUITING · Phase 1
-
Effects of TNX-832 (Sunol cH36) in Subjects With Acute Lung Injury/Acute Respiratory Distress Syndrome
COMPLETED · Phase 1
-
Iloprost Effects on Gas Exchange and Pulmonary Mechanics
COMPLETED · Phase 1
-
A Study of APL-9 in Adults With Mild to Moderate ARDS Due to COVID-19
COMPLETED · Phase 1
-
A Phase 1/2 Study to Assess MultiStem® Therapy in Acute Respiratory Distress Syndrome
COMPLETED · Phase 1
-
JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS (Master Record)
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.